Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies.

Abstract:

BACKGROUND:Direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) therapy has been approved for sepsis-associated acute respiratory distress syndrome, but its efficacy for other rapidly progressive interstitial pneumonias (RPIPs) is unclear. The purpose of this study was to examine the efficacy of PMX-DHP therapy for acute respiratory failure in patients with RPIPs, when compared with a historical control receiving conventional treatment without PMX-DHP. METHODS:This study comprised 77 patients with RPIPs in our institute between January 2002 and December 2015. The initial 36 patients between January 2002 and March 2007 were treated without PMX-DHP (historical control group), and the following 41 patients between April 2007 and December 2015 were treated with PMX-DHP (PMX-DHP group) once daily for two successive days concurrently with corticosteroids and/or immunosuppressive agents. The 90-day mortality and clinical factors were compared between the groups. Cox proportional hazards models were constructed to analyze 90-day mortality and identify predictors. RESULTS:The 90-day mortality rate was significantly lower in the PMX-DHP group than in the controls (41.5% versus 66.7%, p = 0.019). PMX-DHP therapy was significantly associated with mortality (hazard ratio 0.505; 95% confidence interval, 0.270-0.904; p = 0.032). There were significant differences in the serial changes in the PaO2/FiO2 ratio, SOFA score, and blood neutrophil counts from days 0-5 after PMX-DHP between the survivor and non-survivor groups ( p = 0.015, p < 0.001, p = 0.035, respectively). The improved PaO2/FiO2 ratio on day 3 significantly correlated with the change in blood neutrophil counts (rs = -0.431, p = 0.006). CONCLUSIONS:PMX-DHP therapy may be effective in RPIPs patients accompanied by acute respiratory failure and is expected to reduce mortality rates.

journal_name

Ther Adv Respir Dis

authors

Ichiyasu H,Horio Y,Masunaga A,Migiyama Y,Sakamoto Y,Jodai T,Ideguchi H,Okabayashi H,Hamada S,Yoshida C,Hirosako S,Okamoto S,Kohrogi H

doi

10.1177/1753465817708950

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

261-275

issue

7

eissn

1753-4658

issn

1753-4666

journal_volume

11

pub_type

杂志文章,评审
  • Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

    abstract::Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812459899

    authors: Hurley M,Smyth A

    更新日期:2012-12-01 00:00:00

  • The influence of speleotherapy combined with pulmonary rehabilitation on functional fitness in older adults - preliminary report.

    abstract:OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620926952

    authors: Mętel S,Kostrzon M,Adamiak J,Gattner H,Kościelecka D,Sosulska A,Szczygieł E,Golec J

    更新日期:2020-01-01 00:00:00

  • Early predictors for mechanical ventilation in COVID-19 patients.

    abstract:OBJECTIVE:To identify potential predictors for invasive and non-invasive mechanical ventilation in coronavirus disease 2019 (COVID-19) patients. METHODS:This study retrospectively analyzes data of 516 patients with confirmed COVID-19, who were categorized into three groups based on which mechanical ventilation method ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620963017

    authors: Li W,Lin F,Dai M,Chen L,Han D,Cui Y,Pan P

    更新日期:2020-01-01 00:00:00

  • Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy.

    abstract:OBJECTIVE:Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentation therapy in reduci...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究

    doi:10.1177/1753465812438387

    authors: Barros-Tizón JC,Torres ML,Blanco I,Martínez MT,Investigators of the rEXA study group.

    更新日期:2012-04-01 00:00:00

  • Current approaches to pharmacotherapy for smoking cessation.

    abstract::It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smokin...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809353768

    authors: Hudmon KS,Corelli RL,Prokhorov AV

    更新日期:2010-02-01 00:00:00

  • Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice.

    abstract:OBJECTIVES:This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups - NSGS and cognitive behavioral group therapy - CBGT) in combination with bupropion SR for smoking cessation in the field, through a smoking cessation clinic. METHODS:Two-hundred...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1753465809350653

    authors: Rovina N,Nikoloutsou I,Katsani G,Dima E,Fransis K,Roussos C,Gratziou C

    更新日期:2009-12-01 00:00:00

  • Leukotriene modifiers in the treatment of asthma in children.

    abstract::Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809348014

    authors: del Giudice MM,Pezzulo A,Capristo C,Alterio E,Caggiano S,de Benedictis D,Capristo AF

    更新日期:2009-10-01 00:00:00

  • Nintedanib in non-small cell lung cancer: from preclinical to approval.

    abstract::Angiogenesis is a driving force of a tumor's development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and m...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465815579608

    authors: Caglevic C,Grassi M,Raez L,Listi A,Giallombardo M,Bustamante E,Gil-Bazo I,Rolfo C

    更新日期:2015-08-01 00:00:00

  • Electronic cigarettes: an aid in smoking cessation, or a new health hazard?

    abstract::The issue of electronic cigarettes is one of the most controversial topics in public health. There is intense debate and dividing opinions about their use patterns, health effects and association with smoking. This is expected since they were only recently introduced to the market and they refer to a harm-reduction ap...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465817744960

    authors: Farsalinos K

    更新日期:2018-01-01 00:00:00

  • How will telemedicine change clinical practice in chronic obstructive pulmonary disease?

    abstract::Within telehealth there are a number of domains relevant to pulmonary care: telemonitoring, teleassistance, telerehabilitation, teleconsultation and second opinion calls. In the last decade, several studies focusing on the effects of various telemanagement programs for patients with chronic obstructive pulmonary disea...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465818754778

    authors: Vitacca M,Montini A,Comini L

    更新日期:2018-01-01 00:00:00

  • Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin.

    abstract:BACKGROUND:Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicating Pa with tobramycin...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620905279

    authors: Akkerman-Nijland AM,Yousofi M,Rottier BL,Van der Vaart H,Burgerhof JGM,Frijlink HW,Touw DJ,Koppelman GH,Akkerman OW

    更新日期:2020-01-01 00:00:00

  • Use of temperature-controlled laminar airflow in the management of atopic asthma: clinical evidence and experience.

    abstract::Avoidance of allergens in the treatment of asthma has hitherto not achieved significant benefit despite the strong evidence that allergy both increases severity and contributes to exacerbations of asthma. House dust mite, cat and dog allergens are the most common perennial allergic triggers and most avoidance strategi...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465817690505

    authors: Warner JO

    更新日期:2017-04-01 00:00:00

  • Surfactant protein D: a lung specific biomarker in COPD?

    abstract::A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synth...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808088903

    authors: Sin DD,Pahlavan PS,Man SF

    更新日期:2008-04-01 00:00:00

  • Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

    abstract::Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of ad...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618801167

    authors: Hida T

    更新日期:2018-01-01 00:00:00

  • Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.

    abstract:OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/1753465813497527

    authors: Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

    更新日期:2013-10-01 00:00:00

  • Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.

    abstract:AIMS:The Cough Severity Diary (CSD) was developed in accordance with the FDA guidance for patient-reported outcome measures and is focused on capturing the patient's perception of cough in terms of frequency, intensity, and disruption due to their cough. The measure includes a series of seven items asking patients to r...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620915155

    authors: Martin Nguyen A,Bacci E,Dicpinigaitis P,Vernon M

    更新日期:2020-01-01 00:00:00

  • Baseline history of patients using selexipag for pulmonary arterial hypertension.

    abstract:INTRODUCTION:Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary arterial hypertension ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466619843774

    authors: Highland KB,Hull M,Pruett J,Elliott C,Tsang Y,Drake W

    更新日期:2019-01-01 00:00:00

  • An update on the use of indacaterol in patients with COPD.

    abstract::Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465810387810

    authors: Brienza NS,Amor-Carro O,Ramos-Barbón D

    更新日期:2011-02-01 00:00:00

  • Lung transplantation: a review of the optimal strategies for referral and patient selection.

    abstract::One of the great challenges of lung transplantation is to bridge the dichotomy between supply and demand of donor organs so that the maximum number of potential recipients achieve a meaningful benefit in improvements in survival and quality of life. To achieve this laudable goal is predicated on choosing candidates wh...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466619880078

    authors: Mitchell AB,Glanville AR

    更新日期:2019-01-01 00:00:00

  • A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma.

    abstract:BACKGROUND:It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. METHODS:Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted acco...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620981863

    authors: Xu L,Yi M,Tan Y,Yi Z,Zhang Y

    更新日期:2020-01-01 00:00:00

  • Factors determining the quality of life of patients with COPD in primary care.

    abstract:OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究

    doi:10.1177/1753465807086097

    authors: Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.

    更新日期:2007-12-01 00:00:00

  • Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.

    abstract:RATIONALE:Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with different levels of symptom severity. This study compared treatment responses ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620968500

    authors: Vogelmeier CF,Kerwin EM,Bjermer LH,Tombs L,Jones PW,Boucot IH,Naya IP,Lipson DA,Compton C,Barnes N,Maltais F

    更新日期:2020-01-01 00:00:00

  • Therapies for interstitial lung disease: past, present and future.

    abstract::As our understanding of the pathobiology and natural history of the various forms of interstitial lung disease (ILD) has evolved, so have our approaches to treating this heterogeneous group of lung disorders. The earliest pharmacologic agents used to treat various forms of ILD were corticosteroids, and corticosteroids...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808096948

    authors: Kim R,Meyer KC

    更新日期:2008-10-01 00:00:00

  • Narrow-band imaging bronchoscopy in the detection of premalignant airway lesions: a meta-analysis of diagnostic test accuracy.

    abstract:OBJECTIVES:Both autofluorescence imaging bronchoscopy and narrow-band imaging have shown promise in the detection of premalignant airway lesions, each by utilizing different bandwidths of lights for better characterization of the mucosal and submucosal vascular grid. Since previously published meta-analyses have shown ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,meta分析

    doi:10.1177/1753465815589698

    authors: Iftikhar IH,Musani AI

    更新日期:2015-10-01 00:00:00

  • Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.

    abstract:BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF patients have stable dise...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620953783

    authors: Aono Y,Nakamura Y,Kono M,Nakamura H,Yokomura K,Imokawa S,Toyoshima M,Yasui H,Hozumi H,Karayama M,Suzuki Y,Furuhashi K,Enomoto N,Fujisawa T,Inui N,Suda T

    更新日期:2020-01-01 00:00:00

  • Therapeutic perspectives in bronchial vascular remodeling in COPD.

    abstract::COPD may be characterized by significant changes in airway mucosal blood vessels, which may contribute to bronchial airway remodeling. The airway wall is more vascularized in COPD patients than in healthy subjects, though this phenomenon is less evident than in asthmatic patients. The vascular mucosal changes in the a...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808092339

    authors: Zanini A,Chetta A,Olivieri D

    更新日期:2008-06-01 00:00:00

  • Experiences with treprostinil in the treatment of pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy. Systemic prostacy...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812455368

    authors: Stream AR,Bull TM

    更新日期:2012-10-01 00:00:00

  • Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

    abstract::Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465816669662

    authors: Kappen JH,Durham SR,Veen HI,Shamji MH

    更新日期:2017-01-01 00:00:00

  • Use of dry powder inhalers in acute exacerbations of asthma and COPD.

    abstract::To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809103737

    authors: Selroos O,Borgström L,Ingelf J

    更新日期:2009-04-01 00:00:00

  • Endoscopic lung volume reduction coil treatment in patients with very low FEV1: an observational study.

    abstract:BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466618760133

    authors: Simon M,Harbaum L,Oqueka T,Kluge S,Klose H

    更新日期:2018-01-01 00:00:00